Mucomyst for Hepatitis C

This study has suspended participant recruitment.
(Collaborator no longer interested, short of funds)
West Virginia University
Information provided by:
VA Office of Research and Development Identifier:
First received: June 26, 2007
Last updated: January 7, 2010
Last verified: June 2008
The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function

Condition Intervention
Hepatitis C
Drug: N-acetylcysteine(Mucomyst)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Mucomyst (NAC) to Ameliorate Oxidant Stress as Measured by Surrogate Serum in Patients With Hepatitis C

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Measurable oxidant stress [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reduction in viral load of Hep C and changes in Liver Function tests [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 5
Study Start Date: November 2006
Estimated Study Completion Date: June 2008
Estimated Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Drug: N-acetylcysteine(Mucomyst)

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Patient with known hepatitis C

Exclusion Criteria:

  • Patient on another therapy for Hep C
  • Patient on dialysis
  • Patient who are allergic to Mucomyst
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00493610

United States, Ohio
VA Medical Center, Dayton
Dayton, Ohio, United States, 45428
Sponsors and Collaborators
VA Office of Research and Development
West Virginia University
Principal Investigator: Mohammad G. Saklayen, MD VA Medical Center, Dayton
  More Information

No publications provided

Responsible Party: Saklayen, Mohammad - Principal Investigator, Department of Veterans Affairs Identifier: NCT00493610     History of Changes
Other Study ID Numbers: 0031 
Study First Received: June 26, 2007
Last Updated: January 7, 2010
Health Authority: United States: Federal Government

Keywords provided by VA Office of Research and Development:
Oxidant stress
Hepatitis C
Liver disease

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Anti-Infective Agents
Antiviral Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses processed this record on February 11, 2016